ArticleCancer causes & control : CCC2017
History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium.
Article in Cancer causes & control : CCC, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Patient-reported outcomes after long-term period of niraparib maintenance in platinum-sensitive recurrent ovarian cancer: a prospective, multicenter cohort study.Journal of ovarian research · 2026Article
- Hypertension and ovarian cancer risk: a meta-analysis of observational studies.Archives of medical science : AMS · 2026Review
- Pre-treatment nutrition-related indicators and the prognosis of patients with newly diagnosed epithelial ovarian cancer: an ambispective cohort study.Frontiers in nutrition · 2025Article
- Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.Frontiers in oncology · 2024Review
- Long-term survival of nonlocalized epithelial ovarian cancer among women using menopausal hormone therapy prior to diagnosis: The extreme study.International journal of cancer · 2022Article
- Survival in Advanced Epithelial Ovarian Cancer Associated with Cardiovascular Comorbidities and Type 2 Diabetes Mellitus.Current oncology (Toronto, Ont.) · 2021Article
- Report from the 36th Annual Meeting of the Korean Society of Gynecologic Oncology (KSGO).Journal of gynecologic oncology · 2021Article
- [ENTPD5 gene is highly expressed in epithelial ovarian cancer: analysis based on Oncomine database and bioinformatics].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2021Article
- Etiology and management of hypertension in patients with cancer.Cardio-oncology (London, England) · 2021Review
- Mortality and glycemic control among patients with diabetes mellitus and uterine or ovarian cancer.Future science OA · 2020Article
- A Novel Six-Gene Signature for Prognosis Prediction in Ovarian Cancer.Frontiers in genetics · 2020Article
- Anesthetics and long-term survival after cancer surgery-total intravenous versus volatile anesthesia: a retrospective study.BMC anesthesiology · 2019Article
- Ovarian Cancer in Women of African Ancestry (OCWAA) consortium: a resource of harmonized data from eight epidemiologic studies of African American and white women.Cancer causes & control : CCC · 2019Article
- Use of Antihypertensive Medications and Survival Rates for Breast, Colorectal, Lung, or Stomach Cancer.American journal of epidemiology · 2019Article
- Impact of beta blockers on survival outcomes in ovarian cancer: a nationwide population-based cohort study.Journal of gynecologic oncology · 2018Article
- Aclidinium inhibits proliferation and metastasis of ovarian cancer SKOV3 cells via downregulating PI3K/AKT/mTOR signaling pathway.Oncology letters · 2018Article
- Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer.Journal of translational medicine · 2018Article
- Hypertension predicts a poor prognosis in patients with esophageal squamous cell carcinoma.Oncotarget · 2018Article
- Is Ovarian Cancer Prevention Currently Still a recommendation of Our Grandparents?Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2017Review
- History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report.British journal of cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors at 20 institutions in 8 countries.
Funding
Abstract
purposeSurvival following ovarian cancer diagnosis is generally low; understanding factors related to prognosis could be important to optimize treatment. The role of previously diagnosed comorbidities and use of medications for those conditions in relation to prognosis for ovarian cancer patients has not been studied extensively, particularly according to histological subtype.
methodsUsing pooled data from fifteen studies participating in the Ovarian Cancer Association Consortium, we examined the associations between history of hypertension, heart disease, diabetes, and medications taken for these conditions and overall survival (OS) and progression-free survival (PFS) among patients diagnosed with invasive epithelial ovarian carcinoma. We used Cox proportional hazards regression models adjusted for age and stage to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) overall and within strata of histological subtypes.
resultsHistory of diabetes was associated with increased risk of mortality (n = 7,674; HR = 1.12; 95% CI = 1.01-1.25). No significant mortality associations were observed for hypertension (n = 6,482; HR = 0.95; 95% CI = 0.88-1.02) or heart disease (n = 4,252; HR = 1.05; 95% CI = 0.87-1.27). No association of these comorbidities was found with PFS in the overall study population. However, among patients with endometrioid tumors, hypertension was associated with lower risk of progression (n = 339, HR = 0.54; 95% CI = 0.35-0.84). Comorbidity was not associated with OS or PFS for any of the other histological subtypes. Ever use of beta blockers, oral antidiabetic medications, and insulin was associated with increased mortality, HR = 1.20; 95% CI = 1.03-1.40, HR = 1.28; 95% CI = 1.05-1.55, and HR = 1.63; 95% CI = 1.20-2.20, respectively. Ever use of diuretics was inversely associated with mortality, HR = 0.71; 95% CI = 0.53-0.94.
conclusionsHistories of hypertension, diabetes, and use of diuretics, beta blockers, insulin, and oral antidiabetic medications may influence the survival of ovarian cancer patients. Understanding mechanisms for these observations could provide insight regarding treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.